Spots Global Cancer Trial Database for midostaurin
Every month we try and update this database with for midostaurin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation | NCT03951961 | Acute Myeloid L... | Midostaurin | 18 Years - | University of Jena | |
| Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia | NCT03900949 | Acute Myeloid L... | Allogeneic Hema... Cytarabine Daunorubicin Hy... Gemtuzumab Ozog... Midostaurin | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant | NCT02723435 | Acute Myeloid L... Adult Acute Mye... | Midostaurin | 60 Years - | Stanford University | |
| Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia | NCT03900949 | Acute Myeloid L... | Allogeneic Hema... Cytarabine Daunorubicin Hy... Gemtuzumab Ozog... Midostaurin | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT01846624 | Acute Myeloid L... AML (Adult) Wit... AML (Adult) Wit... AML (Adult) Wit... AML (Adult) Wit... AML (Adult) Wit... Secondary AML (... Untreated AML (... | Decitabine Midostaurin | 60 Years - | Stanford University | |
| Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML | NCT01830361 | Acute Myeloid L... | midostaurin (PK... | 18 Years - 65 Years | Technische Universität Dresden | |
| Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia | NCT03836209 | Acute Myeloid L... | Gilteritinib Midostaurin Daunorubicin Cytarabine | 18 Years - 70 Years | PrECOG, LLC. | |
| Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT00651261 | Leukemia | cytarabine daunorubicin midostaurin placebo dexamethasone a... | 18 Years - 59 Years | Alliance for Clinical Trials in Oncology | |
| iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004) | NCT03207334 | Acute Myeloid L... | Midostaurin Cytarabine | 18 Years - 75 Years | University of Florida | |
| A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML | NCT03280030 | Acute Myeloid L... | Midostaurin Placebo | 18 Years - 70 Years | Novartis | |
| A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML | NCT03591510 | FLT3-mutated Ac... | Midostaurin Fludarabine Cytarabine Daunorubicin or... Mitoxantrone Etoposide | 3 Months - 17 Years | Novartis | |
| Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia | NCT04982354 | Acute Myeloid L... | CPX-351 Midostaurin Busulfan Melphalan Fludarabine CD34+ selected ... | 18 Years - 74 Years | Baptist Health South Florida | |
| Managed Access Programs for PKC412, Midostaurin | NCT05219266 | FMS-Like Tyrosi... Acute Myeloid L... Aggressive Syst... Mast Cell Leuke... Systemic Mastoc... | midostaurin | 18 Years - | Novartis | |
| PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT00093600 | Acute Myeloid L... | cytarabine daunorubicin hy... midostaurin | 18 Years - 60 Years | Novartis | |
| Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) | NCT04385290 | Acute Myeloid L... | MODULE: convent... MAGNOLIA-trial:... MAGNOLIA-trial:... MAGMA-trial:GO ... MAGMA-trial: co... | 18 Years - 75 Years | Technische Universität Dresden | |
| Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy | NCT02624570 | Acute Myeloid L... FLT3 Mutation, ... | Midostaurin | 18 Years - | Novartis | |
| An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML) | NCT03114228 | FLT3-mutated Ac... | Midostaurin | 18 Years - | Novartis | |
| Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT00651261 | Leukemia | cytarabine daunorubicin midostaurin placebo dexamethasone a... | 18 Years - 59 Years | Alliance for Clinical Trials in Oncology | |
| Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia | NCT01174888 | Acute Myeloid L... Acute Myeloid L... Myelodysplastic... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Secondary Acute... | midostaurin Bortezomib mitoxantrone hy... etoposide cytarabine | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML | NCT01883362 | Acute Myeloid L... | Midostaurin Standard of Car... | 18 Years - 70 Years | Novartis | |
| Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant | NCT02723435 | Acute Myeloid L... Adult Acute Mye... | Midostaurin | 60 Years - | Stanford University | |
| Protocol in Acute Myeloid Leukemia With FLT3-ITD | NCT01477606 | Acute Myeloid L... | Midostaurin Cytarabine Daunorubicin | 18 Years - 70 Years | University of Ulm | |
| Protocol in Acute Myeloid Leukemia With FLT3-ITD | NCT01477606 | Acute Myeloid L... | Midostaurin Cytarabine Daunorubicin | 18 Years - 70 Years | University of Ulm | |
| A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia | NCT00866281 | Acute Myeloid L... Acute Lymphobla... | midostaurin | 3 Months - 18 Years | Novartis | |
| Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML | NCT01161550 | Leukemia, Myelo... | Granulocyte col... Cladribine Cytarabine All-Trans Retin... Midostaurin | 18 Years - | Washington University School of Medicine | |
| Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia | NCT01093573 | Untreated Adult... | midostaurin azacitidine bone marrow asp... mutation analys... Pharmacokinetic... | - | Case Comprehensive Cancer Center | |
| Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML) | NCT05488613 | Acute Myeloid L... | Midostaurin | 18 Years - 99 Years | Novartis | |
| Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia. | NCT03379727 | Acute Myeloid L... | Midostaurin Cytarabine anthracycline (... | 18 Years - | Novartis | |
| A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML | NCT03591510 | FLT3-mutated Ac... | Midostaurin Fludarabine Cytarabine Daunorubicin or... Mitoxantrone Etoposide | 3 Months - 17 Years | Novartis | |
| A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) | NCT03512197 | Acute Myeloid L... | Midostaurin Placebo Chemotherapy | 18 Years - | Novartis | |
| Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML) | NCT05488613 | Acute Myeloid L... | Midostaurin | 18 Years - 99 Years | Novartis | |
| Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation | NCT03951961 | Acute Myeloid L... | Midostaurin | 18 Years - | University of Jena | |
| Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia | NCT03686345 | Core Binding Fa... | Midostaurin | 18 Years - 65 Years | Niguarda Hospital | |
| Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia | NCT01093573 | Untreated Adult... | midostaurin azacitidine bone marrow asp... mutation analys... Pharmacokinetic... | - | Case Comprehensive Cancer Center | |
| A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia | NCT04075747 | Acute Myeloid L... | CPX-351 Venetoclax Midostaurin Enasidenib | 18 Years - 75 Years | Jazz Pharmaceuticals | |
| A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy | NCT04027309 | Acute Myeloid L... Myelodysplastic... | Gilteritinib Midostaurin | 18 Years - | Stichting Hemato-Oncologie voor Volwassenen Nederland | |
| Revumenib in Combination With 7+3 + Midostaurin in AML | NCT06313437 | Acute Myeloid L... AML, Adult AML With Gene M... AML Leukemia | Revumenib Midostaurin Cytarabine Daunorubicin | 18 Years - 75 Years | Dana-Farber Cancer Institute | |
| A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS | NCT04477291 | Acute Myeloid L... Myelodysplastic... | CG-806 | 18 Years - | Aptose Biosciences Inc. | |
| Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML | NCT01161550 | Leukemia, Myelo... | Granulocyte col... Cladribine Cytarabine All-Trans Retin... Midostaurin | 18 Years - | Washington University School of Medicine | |
| Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML | NCT01830361 | Acute Myeloid L... | midostaurin (PK... | 18 Years - 65 Years | Technische Universität Dresden |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
